180 related articles for article (PubMed ID: 18460523)
1. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
Sirak TE; Sherrid MV
Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
[TBL] [Abstract][Full Text] [Related]
2. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
3. Possible acute and chronic synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report.
Haruki S; Minami Y; Kajimoto K; Yashiro B; Suzuki T; Kawana M; Hagiwara N
Eur J Heart Fail; 2010 Jan; 12(1):94-7. PubMed ID: 19942605
[TBL] [Abstract][Full Text] [Related]
4. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
5. An intraoperative diagnosis of dynamic left ventricular outflow tract obstruction using transesophageal echocardiography leads to the treatment with intravenous disopyramide.
Ashidagawa M; Ohara M; Koide Y
Anesth Analg; 2002 Feb; 94(2):310-2, table of contents. PubMed ID: 11812689
[TBL] [Abstract][Full Text] [Related]
6. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Verlinden NJ; Coons JC
Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
[TBL] [Abstract][Full Text] [Related]
7. Negative ionotropic agents for the treatment of left ventricular outflow tract obstruction due to sigmoid septum and concentric left ventricular hypertrophy.
Ranasinghe I; Yeoh T; Yiannikas J
Heart Lung Circ; 2011 Sep; 20(9):579-86. PubMed ID: 21684204
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography imaging to quantify the area of the endocardial subvalvular apparatus in hypertrophic cardiomyopathy - Relationship to outflow tract obstruction and symptoms.
Tajima M; Iguchi N; Utanohara Y; Hiroi Y; Mahara K; Niwa T; Takayama M; Sumiyoshi T; Tomoike H
J Cardiovasc Comput Tomogr; 2016; 10(5):351-8. PubMed ID: 27498132
[TBL] [Abstract][Full Text] [Related]
11. Hypertrophic cardiomyopathy with right ventricular outflow tract and left ventricular intracavitary obstruction.
Malik R; Maron MS; Rastegar H; Pandian NG
Echocardiography; 2014 May; 31(5):682-5. PubMed ID: 24649889
[TBL] [Abstract][Full Text] [Related]
12. Relationship between outflow obstruction and left ventricular functional impairment in hypertrophic cardiomyopathy: a Doppler echocardiographic study.
Araujo AQ; Arteaga E; Ianni BM; Fernandes F; Ramires FJ; Buck PC; Salemi VM; Nastari L; Mady C
Echocardiography; 2006 Oct; 23(9):734-40. PubMed ID: 16999691
[TBL] [Abstract][Full Text] [Related]
13. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
[TBL] [Abstract][Full Text] [Related]
15. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction.
Schaff HV; Dearani JA; Ommen SR; Sorajja P; Nishimura RA
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):303-9. PubMed ID: 22154797
[TBL] [Abstract][Full Text] [Related]
16. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy.
McIntosh CL; Maron BJ; Cannon RO; Klues HG
Circulation; 1992 Nov; 86(5 Suppl):II60-7. PubMed ID: 1424035
[TBL] [Abstract][Full Text] [Related]
17. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
[TBL] [Abstract][Full Text] [Related]
18. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
Duncan WJ; Tyrrell MJ; Bharadwaj BB
Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
[TBL] [Abstract][Full Text] [Related]
19. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
[TBL] [Abstract][Full Text] [Related]
20. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
Sherrid MV; Arabadjian M
Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
